Targeting p21 degradation locally

Yue Xiong1

  • 1Department of Biochemistry and Biophysics, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, NC 27599, USA. yxiong@email.unc.edu

Developmental Cell
|November 16, 2010
PubMed

Insights

Researchers found a specific E3 ubiquitin ligase, CRL2(LRR1), that targets the cell migration protein p21 in the cytoplasm. This discovery explains how p21

Area of Science:

  • Cell Biology
  • Molecular Biology
  • Protein Regulation

Background:

  • Protein function is often controlled by where it is located within a cell.
  • Regulation of protein activity is crucial for cellular processes.

Discussion:

  • The study identifies CRL2(LRR1) as the E3 ubiquitin ligase responsible for targeting p21.
  • CRL2(LRR1) specifically ubiquitylates p21 in the cytoplasm.
  • This targeted ubiquitylation is essential for enabling cell migration.

Key Insights:

  • Subcellular localization dictates protein regulation.
  • CRL2(LRR1) acts as a cytoplasmic E3 ubiquitin ligase for p21.
  • Cytoplasmic p21 ubiquitylation by CRL2(LRR1) promotes cell migration.

Outlook:

  • Further research can explore the precise mechanisms of CRL2(LRR1) action.
  • Investigating other substrates of CRL2(LRR1) may reveal broader roles.
  • Understanding this pathway could offer insights into diseases involving cell migration.

Related Concept Videos

Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...